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ABSTRACT
Background and the purpose of the study: Bifidobacterial strains are excessively sensitive to 
acidic conditions and this can affect their living ability in the stomach and fermented foods, and 
as a result, restrict their use as live probiotic cultures. The aim of the present study was to obtain 
bifidobacterial isolates with augmented tolerance to simulated gastrointestinal condition using 
cross-protection method.
Methods: Individual bifidobacterial strains were treated in acidic environment and also in 
media containing bile salts and NaCl. Viability of the acid and acid-bile-NaCl tolerant isolates 
was further examined in simulated gastric and small intestine by subsequent incubation of the 
probiotic bacteria in the corresponding media for 120 min. Antipathogenic activities of the 
adapted isolates were compared with those of the original strains.  
Results and major conclusion: The acid and acid-bile-NaCl adapted isolates showed improved 
viabilities significantly (p<0.05) in simulated gastric fluid compared to their parent strains.   
The levels of reduction in bacterial count (Log cfu/ml) of the acid and acid-bile-NaCl adapted 
isolates obtained in simulated gastric fluid ranged from 0.64-3.06 and 0.36-2.43 logarithmic 
units after 120 min of incubation. There was no significant difference between the viability of the 
acid-bile-NaCl-tolerant isolates and the original strains in simulated small intestinal condition 
except for Bifidobacterium adolescentis (p<0.05). The presence of 15 ml of supernatants of 
acid-bile-NaCl-adapted isolates and also those of the initial Bifidobacterium strains inhibited 
pathogenic bacterial growth for 24 hrs. Probiotic bacteria with improved ability to survive in 
harsh gastrointestinal environment could be obtained by subsequent treatment of the strains in 
acid, bile salts and NaCl environments. 
Keywords:  Probiotic,  Bifidobacterium  isolates,  Simulated  gastrointestinal  fluid,  Stress 
adaptation, Cross protection mechanisms
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INTRODUCTION
Probiotics  are  defined  as  ‘live  microbial  foods 
which are associated with beneficial health effects 
on the host when ingested in appropriate amount 
(1). According to this definition, the viability and 
metabolic  activity  of  probiotic  bacteria  should 
be  maintained from  production  to  consumption. 
It is generally recommended that probiotic products 
should contain at least 107 of live microorganisms 
per gram or per milliliter in order to exert their 
beneficial health effects (2, 3). 
The  harsh  conditions  of  the  gastrointestinal  tract 
including the acidic environment of the stomach and 
the bile salts secreted in the duodenum are important 
impediments  to  the  viability  of  ingested  bacteria 
(4, 5). Therefore production of bifidobacteria with 
augmented adaptation to stress conditions is required in 
order to enhance their probiotic characteristics (4, 6). 
Methods  based  on  stress  adaptation  and  cross 
protection  are  currently  of  researcher’s  interests 
(2, 4). Most of the approaches to induce tolerance 
to  the  lethal  stress  circumstances  include  stress 
adaptation and cross-protection mechanisms based 
on exposures of bifidobacterial cells to sub-lethal 
stress-treatments  of  starvation,  heat,  bile,  salts  or 
acidic pH (2, 4). 
The  aim  of  the  present  study  was  to  obtain 
bifidobacterial  isolates  with  improved  probiotic 
properties  and  augmented  resistance  to  simulated 
gastrointestinal condition using cross-protection method. 
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Evaluation  of  tolerance  of  acid  and  acid-bile-
NaCl adapted isolates to simulated gastrointestinal 
conditions
Survival of the acid-bile-NaCl-adapted Bifidobacterium 
isolates in stress environment simulating stomach and 
intestine were assessed while acid-adapted isolates 
were  only challenged in simulated gastric condition. 
Cell suspensions of individual strains (108–109 cells ml-1) 
were incubated in simulated gastric and small intestinal 
fluid as previously described. Aliquots were harvested 
at different times (0, 90, and 120 min) and bacterial 
counts were estimated by plating on MRSC agar media.
Pathogenic bacteria and culture conditions 
The  pathogenic  bacteria  used  in  this  study  were 
purchased  from  PTCC  (Persian  Type  Culture 
Collection,  Iran)  and  included;  Eschershia  coli 
ATCC  8739,  Staphylococcus  aureus  ATCC  6538 
and  Pseudomonas  aueroginosa ATCC  9027  (12). 
Fresh vegetative cultures of the individual bacteria 
were prepared by inoculating bacteria in Caso Agar 
Medium  (Merck  GMBH,  Germany)  and  further 
incubation at 37°C for 24 hrs.  
Phenotypic characterization of the acid-bile-NaCl-
adapted Bifidobacterium isolates
Phenotypic  of  the  acid-bile-NaCl-adapted  isolates 
were  compared  with  the  original  strains  using 
conventional morphological as well as biochemical 
tests.  A cocktail of biochemical tests were conducted 
on the acid-bile-NaCl-adapted Bifidobacterium isolates 
and the results were compared with those of the initial 
strains as well as those in the Bergey’s manual of 
determinative bacteriology. 
Comparison  of  anti-pathogenic  properties  of 
Bifidobacterium strains before and after treatment
Overnight  cultures  of  acid-bile-NaCl-adapted 
Bifidobacterium isolates and also those of the initial 
strains  were  centrifuged  (6,000  rpm,  15  min)  and 
supernatants were filter sterilized. Aliquots of 5 and 
15 ml of supernatants of the individual bifidobacterial 
cultures were added to flasks containing 100 ml of 
Muller Hinton Broth and also 1ml of cultures of the 
pathogenic  bacteria.  Control  flasks  did  not  contain 
bifidobacterial  supernatants.  Flasks  were  incubated 
aerobically  at  37°C  for  24  hrs  and  the  kinetics  of 
growth  of  pathogenic  bacteria  were  determined  by 
taking  samples  in  2  hrs  intervals  and  subsequent 
enumeration of bacteria using the conventional pour 
plate technique. 
Statistical analyses
The  results  are  average  of  triplicate  analyzes. 
Statistical analysis of the data was carried out using 
SPSS  version  11.5.  Statistical  significance  of  the 
difference in survival rates of the adapted isolates 
and the initial bifidobacterium strains in simulated 
gastrointestinal conditions were analyzed by t-test 
MATERIAL   AND  METHODS
Bacterial strains and culture conditions 
The  bacterial  strains  used  in  this  study  were 
Bifidobacterium  angulatum  PTCC  (Persian  Type 
Culture  Collection-Iran)  1366,  Bifidobacterium 
animalis  PTCC  1631,  Bifidobacterium  bifidum  PTCC 
1644 and Bifidobacterium adolescentis PTCC 1536. 
Strains were stored at -70 ºC and routinely sub-cultured 
on  MRS  broth  (Merck  GMBH, Germany) enriched 
with  0.05%  L-cysteine  (Merck  GMBH,  Germany) 
(MRSBC), at 37°C (7). All incubations were performed 
in  anaerobic  jars  (H2/CO2/N2;  10:5:85,  Anoxomat 
WS8000, Mart_ Microbiology, Lichtenvoorde and the 
Netherlands). Bacterial enumeration was conducted by 
plate counting of the cultures on MRSC agar (8). 
 
Evaluation of sensitivity of Bifidobacterium strains to 
artificial gastrointestinal conditions 
The ability of the Bifidobacterium strains to tolerate 
gastrointestinal  transit  was  conducted  according  to 
the  previously  reported  method  (9).  Quantities  of 
individual strains (108–109 cells ml-1) were incubated 
in sterile saline solution (0.5% w ⁄ v NaCl), containing 
3 g/liter pepsin (Merck GMBH, Germany) (pH=2) at 
37°C. Transit tolerance of the strains was evaluated by 
harvesting aliquots at different times (0, 90, and 120 
min) and further plating on MRSC agar. After exposure 
to  simulated  gastric  condition,  cells  were  harvested 
by centrifugation (6,000 rpm, 15 min) and washed in 
sterile saline solution (10). The bacterial cells were 
then exposed to pancreatine (1 g/liter; Merck GMBH, 
Germany) and bile salts (0.5% w/v ox gall; Merck 
GMBH, Germany) in sterile saline solution (0.5% w ⁄ v 
NaCl;  Merck  GMBH,  Germany)  (pH=8).  Aliquots 
were taken after 0, 90 and 120 min and the tolerance to 
small intestinal transit was determined by counting the 
viable cells appearance on MRSC agar enriched with 
L-cysteine hydrochloride (0·05% w/v) ( 11).
Adaptation methods  
Acid adaptation of Bifidobacterium strains
Fresh MRSBC media (pH=2) were inoculated with 1% 
of PBS-washed overnight cultures of the individual 
bifidobacterial  strains. Acid-adapted  isolates  were 
recovered by plating them on MRSC agar at neutral pH 
after incubation at 37 °C for 16 hrs and further storage 
of the plates in anaerobic condition for 3 to 4 days (4).
Bile and Sodium Chloride adaptation of Bifidobacterium 
Strains
Cells of overnight cultures of acid-adapted isolates 
were  harvested  by  centrifugation  (6000  rpm,  15 
min), washed with phosphate-buffered saline (PBS), 
and diluted in fresh MRSBC supplemented with bile 
salts Ox-gall; 3.0 % w ⁄ v and NaCl 10.0 % w ⁄ v. 
Cultures were incubated at 37 °C for 24 hrs, and then 
the acid-bile-NaCl-adapted isolates were recovered 
by plating them on MRSC agar. (4). 59 Autochthonous bifidobacteial isolates
(paired,  one  tailed).  The  results  were  considered 
statistically different at p<0.05.
RESULTS  AND  DISCUSSION
There  is  an  increasing  interest  in  the  use  of 
Bifidobacterium  probiotic  strains  in  functional 
foods  and  pharmaceutical  products.  Initial 
experiments  conducted  by  testing  the  sensitivity 
of the bifidobacterial strains (Table 1) showed the 
lack of Bifidobacterium intrinsic resistance to acidic 
condition such as simulated human gastric condition. 
The ability of the individual bifidobacteria to survive 
in the simulated gastrointestinal transit varied among 
strains. The viability of all of the untreated tested 
strains decreased significantly (p<0.05) in simulated 
gastric juice. The range of loss in viability varied 
from 0.7 to 4.6 logarithmic units after an incubation 
time  of  90  min,  which  was  the  average  contact 
time of the ingested foods with gastric materials. 
The reduction in bacterial counts after 120 min of 
incubation was however, 1.9-7.16 logarithmic units 
(Table 1). B. animalis and B. bifidum seemed to be 
the most resistant strains to the acidic pH showing 
reduction in the bacterial count of about 2 logarithmic 
units after 120 min of incubation in simulated gastric 
fluid. In contrast, B. adolescentis showed to be the 
most vulnerable strain to the simulated gastric fluid 
ending with about 7 logarithmic units reduction in 
its viability after 120 min of incubation. Previous 
studies conducted by other research groups also have 
shown that most of the bifidobactrial strains e.g. B. 
bifidum, B. animalis, B. infantis, B. breve, B. longum 
and B.  adolescentis lacked the intrinsic resistance 
to simulated gastric conditions (pH 2.0 for 90 min) 
(2,  4,  9,  13).This  could  limit  their  application  as 
probiotic  oral  supplement.  Therefore,  approaches 
based on stress adaptation and cross protection were 
applied to achieve improved adapted isolates. It has 
been demonstrated that exposure of B. breve to pH 
5.2 protects cells against lethal pH values of 2.0–
5.0 (14) and exposure of bacteria to stress factors 
(heat, bile salts, or acid pH) can protect them against 
further stress conditions (7). 
The viability of the bifidobacterial strains were not 
                                                                                                     
                                            
                                                                               
Bacterial strain 0 min¥ 90 min
  
120 min 0 min 90 min 120 min
 B. angulatum   9.18  ± 0.04   
 (9.15 ± 0.20)#
 [9.17 ± 0.06]§
6.63  ± 0.12¤*  
(7.16 ± 0.14)* 
[7.23 ± 0.06] ¤ 
4.86 ± 0.58 ¤*
(6.63 ± 0.14)* 
[7.75 ±0.05] ¤ 
8.35  ± 0.13
ND
[8.45 ± 0.16]
8.09  ± 0.15
ND
[8.28 ± 0.21]
7.55  ± 0.22
ND
[8.10 ± 0.25]
 B. animalis     8.75  ± 0.13
 (8.78 ± 0.11)
 [8.82 ± 0.11]
8.05 ± 0.25 *
(8.59 ±0.73)* 
[8.71 ± 0.15] 
6.85 ± 0.11 ¤*
(8.14 ±0.69) *  
[8.46 ± 0.09] ¤
9.12  ± 0.06
ND
[9.12 ± 0.10]
9.02  ±  0.19       
ND
[9.09 ± 0.30]      
 8.87  ± 0.15
ND
[8.87 ± 0.15]
 B. bifidum      8.45  ± 0.11
  (8.52 ± 0.15)   
  [8.48 ± 0.22]
7.25 ± 0.19 ¤
(7.57 ± 0.18)
[7.88± 0.11] ¤
6.28  ±0.12 ¤*
(7.07 ±0.08) *
[7.47 ± 0.39] ¤
8.87  ± 0.10
ND
[8.75 ± 0.41]
8.56  ± 0.25
ND
[8.68 ± 0.11] 
8.11  ± 0.10
ND
[8.53 ± 0.16]
B. adolescentis   9.27  ± 0.05
(9.21 ± 0.47)   
[9.18 ± 0.08]
4.67 ± 0.10 ¤*
(7.25 ±0.31)*
[7.86 ± 0.08] ¤
2.11 ± 0.05 ¤*        
(6.15 ±0.11)*
[6.75 ± 0.61] ¤
8.95  ± 0.11
ND
[8.91 ± 0.11]
7.41  ± 0.05 ¤
ND
[8.13 ± 0.21] ¤
7.05  ± 0.08 ¤
ND
[7.35 ± 0.49] ¤
Viable count (log cfu ml-1; mean ± S.D.۞)
during simulated gastric 
transit tolerance 
 Viable count (log cfu ml-1; mean ± S.D.)
during small intestinal 
transit tolerance
Table 1. Viability of initial Bifidobacterium strains, acid-adapted and acid-bile-NaCl- adapted isolates in gastric and intestinal simulated 
fluid. Isolates were treated by subsequent incubation in acid, bile and salt environment.
      ۞ logarithmic Colony Forming Units per milliliters; mean ± standard deviation     
       ¥  Min  
       #  The figures quoted in parenthesis represent logarithm of survival of acid-adapted isolates.
       §  The figures quoted in closed brackets represent logarithm of survival of acid-bile-NaCl-adapted     
           isolates. 
       *  It shows a significant difference between survivals of acid-adapted isolates with initial strains 
           (p < 0.05).             
        ¤ It shows a significant difference between survivals of acid-bile-NaCl-adapted isolates with initial           
           strains (p < 0.05).
              ND= Not Determined60 Fazeli et al / DARU 2010 18 (1) 57 -63
Figure 1. Growth curves of Escherichia coli in the presence of different volumes (5, 15 ml) of supernatants of the acid-bile-NaCl-
adapted (b & d) treated and initial (a & c) untreated strains.
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Figure 2. Growth curves of Pseudomonas aeruginosa in the presence of different volumes (5, 15 ml) of supernatants of the acid-
bile-NaCl-adapted (b & d) treated and initial (a & c) untreated strains.
Figure 3. Growth curves of Staphylococcus aureus in the presence of different volumes (5, 15 ml) of supernatants of the acid-bile-
NaCl-adapted (b & d) treated and initial (a & c) untreated strains.
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affected  in  simulated  small  intestinal  transit  fluid 
and  were  considered  intrinsically  tolerant  except 
for B. adolescentis (Table 1).The level of reduction 
in bacterial counts by individual bacteria obtained 
in  simulated  small  intestine  fluid  ranged  from 
0.1 to 1.54 and 0.25 to 1.9 logarithmic units after 
90 and 120 min of incubation time respectively. It 
has been reported that the majority of strains were 
intrinsically resistant with no reduction in viability 
after 3 hrs exposure to simulated pancreatic juice 
(9).  In  an  independent  study,  using  a  dynamic 
model of the stomach and the small intestine bile 
apparently played an influential role on the survival 
of  the  Bifidobacterium.  (15).  Pre-treatment  of  B. 
breve, B. animalis and B. longum at pH values of 
5.2, 3.5 and at 47º C showed an effect in protection 
of these bacteria against bile (4). Previous studies 
have demonstrated a relationship between tolerance 
to acidic pH, high bile salt concentrations and high 
temperatures  among  the  Bifidobacterium  strains 
(14, 16, 17). 
The  ability  of  the  acid-bile-NaCl-adapted 
Bifidobacterium  isolates  to  survive  in  the 
simulated  gastrointestinal  juice  and  also  the  ability 
of acid-adapted strains to tolerate simulated gastric 
condition have been depicted in table 1. All the acid 
and acid-bile-NaCl adapted isolates showed better 
survival in artificial gastric juice compared to the 
original strains. The ability of acid and acid-bile-
NaCl adapted isolates to survive in simulated gastric 
fluid was significantly different (p < 0.05) compared 
with their original strains.  The level of reduction in 
bacterial counts (Log cfu/ml) of the acid and acid-
bile-NaCl  adapted  isolates  obtained  after  90  min 
incubation  in  simulated  gastric  fluid  ranged  from 
0.19 to 1.99 and 0.11 to 1.94 respectively while the 
level of reduction in bacterial counts of the acid and 
acid-bile-NaCl adapted isolates obtained in simulated 
gastric fluid ranged from 0.64 to 3.06 and 0.36 to 
2.43 logarithmic units after 120 min of incubation. 
The acid and acid-bile-NaCl adapted isolates showed 
improved viabilities of 0.79 to 4.04 and 1.19 to 4.64 
logarithmic  units  in  simulated  gastric  fluid  after 
120 min of incubation time respectively. However, 
there  was  no  significant  difference  between  the 
viability of the acid-bile-NaCl-adapted isolates and 
initial strains in simulated small intestinal condition 
except for B. adolescentis (p > 0.05). Among the 
bacterial strains adopted in current study B. animalis 
was found to be the most resistant strain while B. 
adolescentis showed to be the most vulnerable to the 
gastrointestinal fluids.
In vitro laboratory and animal studies have shown 
that bifidobacteria exert antagonistic activity against 
pathogens  (18,19).  All  the  adapted  isolates  were 
shown to have kept their initial biochemical patterns 
(data not shown). Supernatants of the adapted strains 
were  tested  for  their  antipathogenic  potentials 
against E. coli, S. aureus, Ps. aueroginosa (Figures 
1-3).  The Presence of 15 ml of supernatants of acid-
bile-NaCl-adapted  isolates  and  also  those  of  the 
initial Bifidobacterium strains inhibited pathogenic 
bacterial growth for 24 hrs while those of the 5 ml 
of supernatants were not affected and could only 
expand the lag phase of the pathogens. 
CONCLUSION
Bifidobacteria are key representatives of probiotic 
bacteria in the functional foods and pharmaceutical 
products.  The  lack  of  their  intrinsic  resistance 
to  simulated  human  gastric  is  a  barrier  for  their 
appropriate probiotic action. The improved properties 
of acid-bile-NaCl-adapted Bifidobacterium isolates 
produced by prolonged exposure to acid, bile and 
NaCl  condition  indicate  that  this  strategy  may 
be  useful  to  enhance  the  stability  and  functional 
properties of probiotic strains. Both stress adaptation 
and cross protection methods were used to achieve 
adapted  bifidobacterial  isolates  with  improved 
tolerance  to  gastrointestinal  transit.  The  adopted 
strains may be used as probiotics in production of 
functional foods.  
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